<DOC>
	<DOCNO>NCT00787033</DOCNO>
	<brief_summary>Phase 1 safety , pharmacokinetics , pharmacodynamics trial focal adhesion kinase ( FAK ) inhibitor PF-04554878 patient advance non-hematologic malignancy , include patient malignancy appropriate serial biopsy . Screening consist medical history , physical examination ECOG performance status , blood draw , pregnancy test female patient childbearing potential , FDG-PET tumor imaging . Treatment consist PF-04554878 pill continue progression disease , unacceptable toxicity , patient request . Evaluations bioactivity measure serial FDG-PET blood test biomarkers related FAK Pyk2 activity .</brief_summary>
	<brief_title>A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies</brief_title>
	<detailed_description />
	<criteria>Patients advance nonhematologic malignancy . Adequate organ function , include bilirubin le 1.5 x ULN , ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . Clinically significant gastrointestinal abnormality , requirement systemic anticoagulant potent CYP 2C8 inhibitor , history clinically significant cardiac pulmonary disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Focal Adhesion Kinase ; Advanced Non-Hematologic Malignancies</keyword>
</DOC>